To evaluate the anti-proliferative effects of regorafenib and silybin treatment, as single agents, we have selected ten human colon cancer cell lines (LoVo, HCT15, SW48, SW48-CR, GEO, GEO-CR, SW620, SW480, HCT116 and LIM1215) that have distinct mutation profiles in KRAS, NRAS, BRAF, and PIK3CA genes. The gene discussed is BRAF; the disease is malignant colon neoplasm.